GF
Graf Finckenstein Friedrich
Directeur Médical
OtherM
Historial del iniciado
DirectivoRendimiento medio T+90
+23.5%
Sobre 1 señal de compra con un rendimiento T+90 consolidado. Base de rendimiento: cierre del día siguiente a la publicación.
Discover the complete record of transactions filed by Graf Finckenstein Friedrich, Directeur Médical. Officer active across 1 company, notably Iovance Biotherapeutics, INC.. Cumulatively, 18 disclosures have been published. History available since 14 June 2022. The latest transaction was disclosed on 5 June 2026 (Retenue fiscale). Regulator: SEC (Form 4). All data is openly available.
Companies and markets linked to Graf Finckenstein Friedrich
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declaraciones18 en total
7813 títulos0Common StockSEC:0001104659-26-071897:0
3976 títulos@ 4,23 US$0.0008% mcap100.0% de su flujoCommon StockSEC:0001104659-26-071897:1
62.497 títulos0Common StockSEC:0001104659-25-021055:0
2813 títulos0Common StockSEC:0001104659-25-004204:0
3906 títulos0Common StockSEC:0001104659-24-125542:0
2813 títulos0Common StockSEC:0001104659-24-109277:0
3907 títulos0Common StockSEC:0001104659-24-097490:0
2813 títulos0Common StockSEC:0001104659-24-080617:0
3906 títulos0Common StockSEC:0001104659-24-068773:0
2812 títulos0Common StockSEC:0001104659-24-048428:0
15.623 títulos0Common StockSEC:0001104659-24-031578:0
2813 títulos0Common StockSEC:0001104659-24-004865:0
2813 títulos0Common StockSEC:0001104659-23-109940:0
2813 títulos0Common StockSEC:0001104659-23-081714:0
2812 títulos0Common StockSEC:0001104659-23-046843:0
11.248 títulos0Common StockSEC:0001104659-23-005048:0
19.690 títulos0Common StockSEC:0001104659-23-001607:0
19.690 títulos0Common StockSEC:0001104659-22-071967:0
About Graf Finckenstein Friedrich
Friedrich Graf Finckenstein serves as Chief Medical Officer at IOVANCE BIOTHERAPEUTICS, INC. In this role, he is responsible for overseeing the medical and clinical aspects of the company's operations. Friedrich brings his expertise to guide product development and ensure compliance with regulatory standards. His leadership is essential for innovation and continuous improvement in the healthcare solutions provided by the company.